Join
Live feed
·
PRReleasevia Quantisnow
ACADIA Pharmaceuticals Inc. logo

Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
ACAD· ACADIA Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACAD (ACADIA Pharmaceuticals Inc.) and more on Quantisnow.